Lifeloc Reports 2020 Full Year Results

Rhea-AI Summary

Lifeloc Technologies (OTC: LCTC) reported its 2020 financial results, revealing a net revenue of $6.357 million, down 27% from 2019's $8.752 million. The company incurred a net loss of $922,000, or $0.38 per diluted share, attributed to the impacts of the COVID-19 pandemic. Despite challenges, Lifeloc received $465,000 in PPP loan forgiveness and launched new products like the LX9 and LT7 devices. The company aims to prioritize the commercialization of the SpinDx technology, enhancing its portfolio in alcohol and drug detection.

Positive

• Achieved $465,000 in PPP loan forgiveness, positively impacting cash flow.
• Introduced new LX9 and LT7 devices, expanding market penetration.
• Plans for rapid deployment of SpinDx technology focused on drug detection.

Negative

• Net revenue declined by 27% to $6.357 million, down from $8.752 million in 2019.
• Reported a net loss of $922,000, compared to a net income of $626,000 in 2019.

WHEAT RIDGE, Colo., March 30, 2021 /PRNewswire/ -- Lifeloc Technologies, Inc. (OTC: LCTC), a global leader in the development and manufacturing of breath alcohol testing devices, has announced financial results for the 2020 fiscal year ended December 31, 2020.

2020 Financial Highlights

Lifeloc Technologies posted annual net revenue of $6.357 million resulting in 2020 after tax net loss of $922 thousand, or a loss of $0.38 per diluted share.  These results compare to net revenue of $8.752 million for 2019, with net income of $626 thousand, or $0.26 per diluted share.  The 2019 results included a one-time gain of $225 thousand from a licensing settlement. 

The COVID-19 global pandemic and the government ordered shutdowns that came along with the pandemic significantly impacted our business.  These unprecedented circumstances caused a departure from Lifeloc's consistent annual profitability and resulted in a 27% decline in revenues for 2020.  This pandemic has impacted operations, adding costs while suppressing our workplace, law enforcement and international markets.  Ironically, a recent study published online in the Journal of the American Medical Association Network shows an average increase in heavy alcohol drinking days of 19% during the pandemic and lockdown, indicating a greater need for Lifeloc products and potentially a pent-up market demand.  On top of the pandemic, extended protests across the country impacted domestic law enforcement, diverting attention and funding.  On a brighter note, with a greater emphasis on workplace hygiene, the pandemic did create openings and demonstrated the value of our hands-free Sentinel™ access control unit.

The Federal government's response to the pandemic included efforts to stabilize the economy and employment.  The most relevant program to Lifeloc was the Paycheck Protection Program (PPP).  As previously reported in 2020, Lifeloc received a $465 thousand SBA guaranteed loan, which could be completely forgiven by the SBA if the proceeds were spent in accordance with the program rules.  Lifeloc complied with this program and applied for forgiveness in 2020, which was granted by the SBA in early 2021.  The financial impact of the forgiveness will be realized in the first quarter of 2021.  The PPP program was quite successful in mitigating the negative effect of the significant demand suppression on cash flow from the pandemic while allowing Lifeloc to carefully reduce structural costs and retain critical personnel, thus enabling us to continue our product development efforts. 

Lifeloc qualified for and received a round two PPP loan of $471 thousand in Q1 of 2021.  As with the first loan, Lifeloc intends to comply with all requirements and will apply for forgiveness of this loan when the program conditions are satisfied and the opportunity to apply becomes available. 

Despite all the challenges of 2020, Lifeloc has made substantial progress on several fronts toward our vision of becoming the leading company in real-time drug and alcohol detection and monitoring.  In 2020, Lifeloc was audited and achieved first time accreditation under the ISO 17034 standards.  As a result, our Plus 4™ alcohol simulator solution can now be called Certified Reference Solution.  As a result, we now have a few additional state governments evaluating Lifeloc as a preferred vendor of these solutions to their various facilities.  We believe we can manufacture and distribute this product more cost effectively than can the individual states. 

Concerns over virus spread led to significant attention to the hygiene and safety of every activity in the marketplace, including breath alcohol testing.  As previously reported, Lifeloc commissioned an independent third-party laboratory to test for any potential of viral cross contamination of test subjects using Lifeloc brand breath alcohol testers.  The conclusion was there is no risk of viral cross contamination using Lifeloc brand breath alcohol testers, which has increased confidence in the Lifeloc brand.

Our new platform LX9 and LT7 devices were introduced late in 2019.  Even in the difficult market conditions of 2020, the features and performance of the new L-series products has driven penetration and opened previously unaddressable market needs, such as requirements for a wide temperature range and fast customization in local languages.  We expect that most L-series sales will be incremental to FC-series devices rather than replacing FC-series sales. 

We continue to invest in the significant growth opportunities of alcohol monitoring and drug detection.  The monitoring opportunity will be addressed primarily through the redesigned Real-Time Alcohol Detection and Reporting (R.A.D.A.R.^®) device.  Manufacture of the second generation R.A.D.A.R. 200 protype devices began in early 2020.  Testing of these redesigned R.A.D.A.R. devices and integration with the monitoring system has been extensive, requiring additional modification before final release.  This design has been finalized with several devices now in field testing and sales release planned very soon. 

Rapid detection of drugs of abuse is the best convergence of current market need and Lifeloc's capabilities, and therefore this is our most important goal.  Additional resources are being deployed to finalizing the development of the SpinDx™ technology and the rapid, quantitative marijuana breathalyzer built on that platform.  We have improved the detection sensitivity for delta-9-THC as well as the device robustness.  Work continues to build this system into a device that can be used for roadside testing.

"2020 was a difficult year with the global pandemic adding costs and impacting demand and the way that we work," commented Dr. Wayne Willkomm, President and CEO.  "We hope to see the continued pickup of our general business conditions as well as the broader adoption of the new LX platform and the imminent release of the redesigned R.A.D.A.R 200 devices return Lifeloc to growth and profitability.  Following the release of the R.A.D.A.R. 200 device, the next big milestone for Lifeloc will be the commercialization of the SpinDx platform.  Speeding the SpinDx commercialization will be prioritized even at the expense of short-term profitability."

About Lifeloc Technologies

Lifeloc Technologies, Inc. (OTC: LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers.  Lifeloc stock trades over-the-counter under the symbol LCTC.  We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, expectations about new and existing products, market demand, acceptance of new and existing products, technologies and opportunities, market size and growth, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled "Risk Factors" in our SEC filings.

EasyCal® and R.A.D.A.R.® are registered trademarks of Lifeloc Technologies, Inc.

Sentinel™ and Plus 4™ are trademarks of Lifeloc Technologies, Inc.

SpinDx™ is a trademark of Sandia Corporation.

Amy Evans 
Lifeloc Technologies, Inc. 
http://www.lifeloc.com 
(303) 431-9500

LIFELOC TECHNOLOGIES, INC.
Balance Sheets
ASSETS
			December 31,
CURRENT ASSETS:			2020			2019
	Cash	$	2,195,070		$	3,185,996
	Accounts receivable, net		523,603			641,239
	Inventories, net		2,498,126			1,986,299
	Income taxes receivable		220,657			6,750
	Prepaid expenses and other		77,962			18,857
	Total current assets		5,515,418			5,839,141
PROPERTY AND EQUIPMENT, at cost:
	Land		317,932			317,932
	Building		1,928,795			1,928,795
	Real-time Alcohol Detection And Recognition equipment and software		569,448			569,448
	Production equipment, software and space modifications		958,785			976,621
	Training courses		432,375			432,375
	Office equipment, software and space modifications		216,618			208,986
	Sales and marketing equipment and space modifications		226,356			232,600
	Research and development equipment, software and space modifications		190,818			172,429
	Less accumulated depreciation		(2,277,839)			(1,959,541)
	Total property and equipment, net		2,563,288			2,879,645
OTHER ASSETS:
	Patents, net		144,702			145,323
	Deposits and other		164,798			74,027
	Deferred taxes		148,142			86,658
	Total other assets		457,642			306,008
	Total assets	$	8,536,348		$	9,024,794
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
	Accounts payable	$	333,851		$	261,798
	Term loan payable, current portion		46,936			44,879
	Paycheck Protection loan payable		465,097			-
	Customer deposits		155,295			214,031
	Accrued expenses		266,266			290,458
	Deferred revenue, current portion		41,053			45,874
	Reserve for warranty expense		46,500			45,000
	Total current liabilities		1,354,998			902,040
TERM LOAN PAYABLE, net of current portion and
	debt issuance costs		1,277,531			1,324,467
DEFERRED REVENUE, net of current portion			3,177			6,066
	Total liabilities		2,635,706			2,232,573
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
	Common stock, no par value; 50,000,000 shares
	authorized, 2,454,116 shares outstanding		4,633,655			4,603,304
	Retained earnings		1,266,987			2,188,917
	Total stockholders' equity		5,900,642			6,792,221
	Total liabilities and stockholders' equity	$	8,536,348		$	9,024,794

 

LIFELOC TECHNOLOGIES, INC.
Statements of Income
		Years Ended December 31,
REVENUES:			2020			2019
	Product sales	$	6,122,348		$	8,251,570
	Royalties		148,398			411,111
	Rental income		85,956			89,142
	Total		6,356,702			8,751,823
COST OF SALES			4,176,156			4,815,820
GROSS PROFIT			2,180,546			3,936,003
OPERATING EXPENSES:
	Research and development		1,007,297			1,038,227
	Sales and marketing		1,074,249			1,240,773
	General and administrative		1,254,503			1,175,788
	Total		3,336,049			3,454,788
OPERATING INCOME (LOSS)			(1,155,503)			481,215
OTHER INCOME (EXPENSE):
	Settlement proceeds		-			225,199
	Interest income		14,294			38,750
	Interest expense		(56,129)			(57,802)
	Total		(41,835)			206,147
NET INCOME (LOSS) BEFORE PROVISION FOR TAXES			(1,197,338)			687,362
BENEFIT FROM (PROVISION FOR) FEDERAL AND STATE INCOME TAXES			275,408			(61,536)
NET INCOME (LOSS)		$	(921,930)		$	625,826
NET INCOME (LOSS) PER SHARE, BASIC		$	(0.38)		$	0.26
NET INCOME (LOSS) PER SHARE, DILUTED		$	(0.38)		$	0.26
WEIGHTED AVERAGE SHARES, BASIC			2,454,116			2,454,116
WEIGHTED AVERAGE SHARES, DILUTED			2,454,116			2,454,116

 

Lifeloc Technologies, Inc.
Statements of Stockholders' Equity
		Years Ended December 31,
		2020			2019
Total stockholders' equity, beginning balances		$	6,792,221		$	6,160,737
Common stock (no shares issued during periods):
	Beginning balances		4,603,304			4,597,646
	Stock based compensation expense related
	to stock options		30,351			5,658
	Ending balances		4,633,655			4,603,304
Retained earnings:
	Beginning balances		2,188,917			1,563,091
	Net income (loss)		(921,930)			625,826
	Ending balances		1,266,987			2,188,917
Total stockholders' equity, ending balances		$	5,900,642		$	6,792,221

 

LIFELOC TECHNOLOGIES, INC.
Statements of Cash Flows
			Years  Ended December 31,
CASH FLOWS FROM OPERATING ACTIVITIES:			2020			2019
	Net income (loss)		$	(921,930)		$	625,826
	Adjustments to reconcile net income (loss) to net cash
	provided from operating activities-
	Depreciation and amortization			364,336			412,529
		Provision for doubtful accounts, net change		24,000			-
	Provision for inventory obsolescence, net change			20,000			20,000
	Deferred taxes, net change			(61,484)			(6,789)
	Reserve for warranty expense, net change			1,500			5,000
	Stock based compensation expense related to
	stock options			30,351			5,658
	Changes in operating assets and liabilities-
	Accounts receivable			93,636			33,897
	Inventories			(531,827)			(715,692)
	Income taxes receivable			(213,907)			83,879
	Prepaid expenses and other			(59,105)			16,298
	Deposits and other			(90,771)			66,425
	Accounts payable			72,053			(81,985)
	Customer deposits			(58,736)			194,766
	Accrued expenses			(24,192)			39,546
	Deferred revenue			(7,710)			(490)
		Net cash provided from (used in)
		operating activities		(1,363,786)			698,868
CASH FLOWS FROM INVESTING ACTIVITIES:
	Purchases of property, equipment and space modifications			(27,477)			(256,906)
	Patent filing expense			(18,796)			-
		Net cash (used in) investing activities		(46,273)			(256,906)
CASH FLOWS FROM FINANCING ACTIVITIES:
	Proceeds from Paycheck Protection loan			465,097			-
	Principal payments made on term loan			(45,964)			(44,293)
		Net cash provided from (used in)
		financing activities		419,133			(44,293)
NET INCREASE (DECREASE) IN CASH				(990,926)			397,669
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD				3,185,996			2,788,327
CASH AND CASH EQUIVALENTS, END OF PERIOD			$	2,195,070		$	3,185,996
SUPPLEMENTAL INFORMATION:
	Cash paid for interest		$	55,045		$	56,717
	Cash paid for income tax		$	-		$	38,000

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/lifeloc-reports-2020-full-year-results-301259082.html

SOURCE Lifeloc Technologies

FAQ

What were Lifeloc Technologies' financial results for 2020?

Lifeloc Technologies reported a net revenue of $6.357 million and a loss of $922,000 for the year 2020.

How did the COVID-19 pandemic affect Lifeloc Technologies?

The pandemic led to a 27% drop in revenues, significantly impacting business operations and demand.

What is the stock symbol for Lifeloc Technologies?

Lifeloc Technologies trades under the stock symbol LCTC.

What key products did Lifeloc Technologies launch in 2020?

The company introduced the LX9 and LT7 devices, enhancing their offerings in alcohol detection.

What financial assistance did Lifeloc Technologies receive in response to the pandemic?

Lifeloc received a $465,000 PPP loan, which was later forgiven, aiding its cash flow.